LightPath Technologies Reports Third Quarter Fiscal 2025 Financial Results

By PR Newswire | May 15, 2025, 4:05 PM

ORLANDO, Fla., May 15, 2025 /PRNewswire/ -- LightPath Technologies, Inc. (NASDAQ: LPTH) ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced financial results for its fiscal third quarter ended March 31, 2025.

Financial Summary:



Three Months Ended March 31,



$ in millions

2025

2024

% Change

Revenue

$9.2

$7.7

19.1 %

Gross Profit

$2.7

$1.6

65.9 %

Operating Expenses

$6.0

$4.2

42.9 %

Net Income (Loss)

($3.6)

($2.6)

37.1 %

Adj. EBITDA* (non-GAAP)

($2.0)

($1.5)

(31.3 %)











 

Third Quarter Fiscal 2025 & Subsequent Highlights: 

  • Closed the acquisition of G5 Infrared ("G5"), a leading high-end infrared camera systems manufacturer, part of LightPath's strategic vision to become a leading vertically-integrated infrared imaging solutions provider.
  • Awarded an initial $2.2 million engineering development model (EDM) order for infrared cameras by L3Harris Technologies to support the Navy's Shipboard Panoramic Electro-Optic/Infrared (SPEIR) Program.
  • Received a $4.8 million initial qualification order for infrared cameras with a new defense industry customer, for planned delivery in calendar year 2025.
  • Secured $4.9 million order for cooled infrared cameras with existing defense customer, for planned delivery in fiscal 2026.
  • Participated in leading industry and investor conferences including the Photonics Spectra Infrared Imaging Summit 2025, SPIE Defense + Commercial Sensing, Advanced Infrared Solutions at 2025 Border Security Expo, 27th Annual Needham Growth Conference, and Sequire Investor Summit Puerto Rico.

Management Commentary

Sam Rubin, President and Chief Executive Officer of LightPath, said: "The closing of our acquisition of G5 Infrared, and the subsequent three significant orders for this new subsidiary, helped to accelerate execution of our strategic vision to become a leading vertically-integrated infrared imaging solutions provider in the $9 billion infrared imaging market. G5 provides a highly incremental offering to LightPath, providing a broad range of cooled infrared camera solutions and assemblies, ranging from high performance mid wave zoom thermal imaging camera systems to thin film deposition services on a variety of infrared substrates, all of which are complementary to our line of uncooled infrared cameras, infrared optics and infrared materials.

"G5's significant pipeline of new business opportunities, with multiple program awards expected to begin production in the next two years, was highlighted recently by three new orders that validate our accretive acquisition. A $4.8 million initial qualification order with a new defense industry customer and a $4.9 million follow-on order with an existing defense industry customer was followed by an initial $2.2 million engineering development model order by L3Harris Technologies – all of which were for infrared cameras from our growing portfolio of cooled and uncooled camera solutions. G5's revenue is primarily driven by established multi-year contracts and multiple programs of record in shipboard long-range surveillance, border security, and counter UAS systems, as well as recurring federal, naval, and law enforcement programs. We expect to add significant value beyond G5's initial accretive revenue stream and believe the acquisition will continue to drive future growth with its higher average selling price and higher-margin cooled infrared camera offerings, incremental products, as well as notable operational synergies – such as integrating their offerings with our proprietary BlackDiamond™ glass and in-house optics manufacturing capabilities.

"Looking ahead, we expect continued momentum for our product portfolio and market potential with our Germanium-free BlackDiamond™ infrared imaging solutions. With supply chain issues plaguing competing Germanium based solutions – such as China's recent ban on the export of Germanium to the United States – our BlackDiamond products are becoming increasingly important to customers. While the China ban has of course impacted the small proportion of our legacy business that still leverages Germanium, we continue to transition our business to utilize our BlackDiamond™ solutions.

"We are moving forward with key defense programs, including our bid to produce a design of a major missile program for the U.S. Army with Lockheed Martin. We are now starting to deliver flightworthy hardware for implementation into Lockheed Martin's initial live program test units and believe the U.S. Army could potentially make a contractor selection decision late this year or early next year. With the integration of G5, we believe we are well positioned to be the optical solutions provider of choice for high value customers with an accelerating pipeline of government and military projects with key defense customers," concluded Rubin.

Third Quarter Fiscal 2025 Financial Results

Revenue for the third quarter of fiscal 2025 increased 19.1% to $9.2 million, as compared to $7.7 million in the same quarter of the prior fiscal year. Revenue was split amongst the Company's product groups in the third quarter of fiscal 2025 as follows:

Product Group Revenue

($ in millions)**

Third Quarter of

Fiscal 2025

Third Quarter of

Fiscal 2024

% Change

Infrared Components

$3.6

$3.6

0 %

Visible Components

$2.8

$2.7

6 %

Assemblies & Modules

$1.9

$0.8

123 %

Engineering Services

$0.8

$0.5

54 %

** Numbers may not foot due to rounding

Gross profit increased 65.9% to $2.7 million, or 29.1% of total revenues, in the third quarter of 2025, as compared to $1.6 million, or 20.9% of total revenues, in the same quarter of the prior fiscal year. The increase in gross margin as a percentage of revenue is primarily due to a more favorable product mix, with more revenue from assemblies and modules and engineering services, which typically have higher margins than infrared components.

Operating expenses increased 42.9% to $6.0 million for the third quarter of fiscal 2025, as compared to $4.2 million in the same quarter of the prior fiscal year. The increase was primarily due to higher legal and consulting fees related to business development and strategic initiatives, including expenses associated with the G5 acquisition, as well as increased sales and marketing spend to promote new products and an increase in materials spend for internally funded new product development projects.

Net loss in the third quarter of fiscal 2025 totaled $3.6 million, or $0.09 per basic and diluted share, as compared to $2.6 million, or $0.07 per basic and diluted share, in the same quarter of the prior fiscal year.

Adjusted EBITDA* loss for the third quarter of fiscal 2025 was $2.0 million, compared to a loss of $1.5 million for the same period of the prior fiscal year. 

Third Quarter Fiscal 2025 Earnings Call

Management will host an investor conference call at 5:00 p.m. Eastern time today, Thursday, May 15, 2025, to discuss the Company's third quarter fiscal 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Date: Thursday, May 15, 2025  

Time: 5:00 p.m. Eastern time  

U.S. Dial-in: 1-877-425-9470 

International Dial-in: 1-201-389-0878 

Conference ID: 13749941 

Webcast: LPTH Q3 FY2025 Earnings Conference Call

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through Thursday, May 29, 2025. To listen, please call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 13749941. A webcast replay will also be available using the webcast link above.

About LightPath Technologies

LightPath Technologies, Inc. (NASDAQ: LPTH) is a leading provider of next-generation optics and imaging systems for both defense and commercial applications. As a vertically integrated solutions provider with in-house engineering design support, LightPath's family of custom solutions range from proprietary BlackDiamond™ chalcogenide-based glass materials – sold under exclusive license from the U.S. Naval Research Laboratory – to complete infrared optical systems and thermal imaging assemblies. The Company's primary manufacturing footprint is located in Orlando, Florida with additional facilities in Texas, New Hampshire, Latvia and China. To learn more, please visit www.lightpath.com.

*Use of Non-GAAP Financial Measures

To provide investors with additional information regarding financial results, this press release includes references to EBITDA and adjusted EBITDA, which are non-GAAP financial measures. The Company calculates EBITDA by adjusting net income to exclude net interest expense, income tax expense or benefit, depreciation, and amortization. We also calculate adjusted EBITDA, which excludes: (1) the effect of the non-cash income or expense associated with the mark-to-market adjustments, related to the warrants; and (2) the loss on extinguishment of debt. The fair value of the warrants is re-measured each reporting period until the warrants are either exercised or expired (which expiration occurs on February 18, 2031).

A "non-GAAP financial measure" is generally defined as a numerical measure of a company's historical or future performance that excludes or includes amounts, or is subject to adjustments, so as to be different from the most directly comparable measure calculated and presented in accordance with GAAP. The Company's management believes that these non-GAAP financial measures, when considered together with the GAAP financial measures, provide information that is useful to investors in understanding period-over-period operating results separate and apart from items that may, or could, have a disproportionately positive or negative impact on results in any particular period. Management also believes that these non-GAAP financial measures enhance the ability of investors to analyze underlying business operations and understand performance. In addition, management may utilize these non-GAAP financial measures as guides in forecasting, budgeting, and planning. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures presented in accordance with GAAP. A reconciliation of these non-GAAP financial measures with the most directly comparable financial measures calculated in accordance with GAAP is presented in the table below.

LIGHTPATH TECHNOLOGIES, INC.

Reconciliation of Non-GAAP Financial Measures and Regulation G Disclosure











(unaudited)







Three Months Ended

March 31,





Nine Months Ended

March 31,







2025





2024





2025





2024



Net loss



$

(3,560,349)





$

(2,597,534)





$

(7,795,091)





$

(5,653,573)



Depreciation and amortization





1,463,150







1,042,850







3,356,752







2,985,850



Income tax provision





100,031







5,798







160,192







121,402



Interest expense





498,862







37,649







817,275







149,048



 EBITDA



$

(1,498,306)





$

(1,511,237)





$

(3,460,872)





$

(2,397,273)



Loss on extinguishment of debt





418,502















418,502











Change in fair value of warrant liability





(904,694)















(904,694)











Adjusted EBITDA



$

(1,984,498)





$

(1,511,237)





$

(3,947,064)





$

(2,397,273)



% of revenue





-22

%





-20

%





-16

%





-10

%

 

Forward-Looking Statements

This press release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "guidance," "plan," "estimate," "will," "would," "project," "maintain," "intend," "expect," "anticipate," "prospect," "strategy," "future," "likely," "may," "should," "believe," "continue," "opportunity," "potential," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, without limitation, statements regarding: (i) anticipated timing for program awards, as well as any resulting impact on our financial performance; (ii) the impact of the G5 acquisition on our business and results of operations; (iii) the performance of our product portfolio and expected market potential with our products and (iv) expectations regarding our ability to secure government and military projects with certain customers. These forward-looking statements are based on information available at the time the statements are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, the impact of varying demand for the Company products; the ability of the Company to obtain needed raw materials and components from its suppliers; the impact of tariffs and other governmental trade restrictions; actions governments, businesses, and individuals take in response to the pandemic, including restrictions on onsite commercial interactions; general economic uncertainty in key global markets and a worsening of global economic conditions or low levels of economic growth; geopolitical tensions, the Russian-Ukraine conflict, and the Hamas/ Israel war; the effects of steps that the Company could take to reduce operating costs; the inability of the Company to sustain profitable sales growth, convert inventory to cash, or reduce its costs to maintain competitive prices for its products; circumstances or developments that may make the Company unable to implement or realize the anticipated benefits, or that may increase the costs, of its current and planned business initiatives; and those factors detailed by the Company in its public filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K and other filings with the SEC. Should one or more of these risks, uncertainties, or facts materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by the forward-looking statements contained herein. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

LIGHTPATH TECHNOLOGIES, INC.

Condensed Consolidated Balance Sheets

(unaudited)











March 31,





June 30,



Assets



2025





2024



Current assets:













Cash and cash equivalents



$

6,478,885





$

3,480,268



Trade accounts receivable, net of allowance of $23,514 and $25,676





7,651,086







4,928,931



Inventories, net





12,687,225







6,551,059



Prepaid expenses and deposits





1,206,115







445,900



Other current assets





57,815







131,177



 Total current assets





28,081,126







15,537,335





















Property and equipment, net





15,461,601







15,210,612



Operating lease right-of-use assets





6,457,530







6,741,549



Intangible assets, net





21,476,226







3,650,739



Goodwill





9,741,473







6,764,127



Deferred tax assets, net





123,000







123,000



Other assets





79,860







59,602



Total assets



$

81,420,816





$

48,086,964



Liabilities and Stockholders Equity

















Current liabilities:

















Accounts payable



$

5,737,240





$

3,231,713



Accrued liabilities





3,079,036







1,911,867



Accrued payroll and benefits





1,752,940







1,446,452



Operating lease liabilities, current





1,271,740







1,059,998



Loans payable, current portion





185,631







209,170



Finance lease obligation, current portion





203,954







177,148



 Total current liabilities





12,230,541







8,036,348





















Deferred tax liabilities, net





1,498,479







326,197



Accrued liabilities, noncurrent





937,000







611,619



Finance lease obligation, less current portion





457,441







528,753



Operating lease liabilities, noncurrent





7,518,766







8,058,502



Loans payable, less current portion





4,693,544







325,880



Warrant liability





4,116,357











Total liabilities





31,452,128







17,887,299





















Commitments and Contingencies



































Series G Convertible Preferred Stock; $0.01 par value



$

34,399,622





























Stockholders equity:

















Preferred stock: Series D, $.01 par value, voting;

















500,000 shares authorized; none issued and outstanding

















Common stock: Class A, $.01 par value, voting;

















94,500,000 shares authorized;

















42,893,563 and 39,254,643 shares issued and outstanding





428,936







392,546



Additional paid-in capital





238,327,729







245,140,758



Accumulated other comprehensive income





451,067







509,936



Accumulated deficit





(223,638,666)







(215,843,575)



Total stockholders equity





15,569,066







30,199,665



Total liabilities, convertible preferred stock and stockholders equity



$

81,420,816





$

48,086,964



 

LIGHTPATH TECHNOLOGIES, INC.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(unaudited)











Three Months Ended





Nine Months Ended







March 31,





March 31,







2025





2024





2025





2024



Revenue, net



$

9,167,627





$

7,699,175





$

24,992,837





$

23,092,060



Cost of sales





6,503,526







6,092,988







17,553,476







16,985,846



Gross profit





2,664,101







1,606,187







7,439,361







6,106,214



Operating expenses:

































Selling, general and administrative





4,448,359







3,171,770







11,075,005







8,691,395



New product development





757,938







569,962







1,998,775







1,817,598



Amortization of intangible assets





779,025







434,403







1,469,512







1,201,120



Loss on disposal of property and equipment





2,068







13,248







80,505







13,248



Total operating expenses





5,987,390







4,189,383







14,623,797







11,723,361



Operating loss





(3,323,289)







(2,583,196)







(7,184,436)







(5,617,147)



Other income (expense):

































Interest expense, net





(498,862)







(37,649)







(817,275)







(149,048)



Loss on extinguishment of debt





(418,502)















(418,502)











Change in fair value of warrant liability





904,694















904,694











Other income (expense), net





(124,359)







29,109







(119,380)







234,024



Total other income (expense), net





(137,029)







(8,540)







(450,463)







84,976



Loss before income taxes





(3,460,318)







(2,591,736)







(7,634,899)







(5,532,171)



Income tax provision





100,031







5,798







160,192







121,402



Net loss



$

(3,560,349)





$

(2,597,534)





$

(7,795,091)





$

(5,653,573)



Foreign currency translation adjustment





120,572







(112,356)







(58,869)







22,409



Comprehensive loss



$

(3,439,777)





$

(2,709,890)





$

(7,853,960)





$

(5,631,164)



Loss per common share (basic)



$

(0.09)





$

(0.07)





$

(0.19)





$

(0.15)



Number of shares used in per share calculation (basic)





41,363,643







37,988,770







40,209,657







37,639,464



Loss per common share (diluted)



$

(0.09)





$

(0.07)





$

(0.19)





$

(0.15)



Number of shares used in per share calculation (diluted)





41,363,643







37,988,770







40,209,657







37,639,464



 

LIGHTPATH TECHNOLOGIES, INC.

Condensed Consolidated Statements of Changes in Stockholders' Equity

(unaudited)

 











Temporary

Equity























Accumulated



















Series G

Convertible





Class A





Additional





Other











Total







Preferred Stock





Common Stock





Paid-in





Comprehensive





Accumulated





Stockholders







Shares





Amount





Shares





Amount





Capital





Income





Deficit





Equity



Balances at June 30, 2024

















39,254,643





$

392,546





$

245,140,758





$

509,936





$

(215,843,575)





$

30,199,665



Issuance of common stock for:





























































Employee Stock Purchase Plan

















8,232







82







10,290























10,372



Exercise of Stock Options, RSUs & RSAs, net

















70,309







703







(703)



























Issuance of common stock for acquisition of Visimid

















279,553







2,796







318,562























321,358



Stock-based compensation on stock options, RSUs & RSAs

































264,475























264,475



Foreign currency translation adjustment









































271,594















271,594



Net loss 

















































(1,622,745)







(1,622,745)



Balances at September 30, 2024

















39,612,737





$

396,127





$

245,733,382





$

781,530





$

(217,466,320)





$

29,444,719



Issuance of common stock for:





























































Exercise of Stock Options, RSUs & RSAs, net

















229,097







2,291







(2,291)



























Shares issued as compensation

















49,000







490







89,180























89,670



Stock-based compensation on stock options, RSUs & RSAs

































231,581























231,581



Foreign currency translation adjustment









































(451,035)















(451,035)



Net loss 

















































(2,611,997)







(2,611,997)



Balances at December 31, 2024

















39,890,834





$

398,908





$

246,051,852





$

330,495





$

(220,078,317)





$

26,702,938



Issuance of preferred stock under private equity placement, net of fees





255







20,968590























(1,320,102)























(1,320,102)



Issuance of common stock for:

































































Employee Stock Purchase Plan





















1,137







11







4,002























4,013



Exercise of Stock Options, RSUs & RSAs, net





















238,641







2,387







788























3,175



Issuance of common stock for acquisition of Visimid





















102,700







1,027







391,561























392,588



Issuance of common stock for acquisition of G5





















1,972,501







19,725







4,852,343























4,872,068



Issuance of common stock under private equity placement, net of fees





















687,750







6,878







1,584,014























1,590,892



Preferred cumulative dividends plus accretion













13,431,032























(13,431,032)























(13,431,032)



Stock-based compensation on stock options, RSUs & RSAs





































194,303























194,303



Foreign currency translation adjustment













































120,572















120,572



Net loss 





















































(3,560,349)







(3,560,349)



Balances at March 31, 2025 





255





$

34,399,622







42,893,563





$

428,936





$

238,327,729





$

451,067





$

(223,638,666)





$

15,569,066





































































Balances at June 30, 2023 





















37,344,739





$

373,447





$

242,808,771





$

606,536





$

(207,836,229)





$

35,952,525



Issuance of common stock for:

































































Employee Stock Purchase Plan





















14,607







146







19,573























19,719



Exercise of Stock Options, RSUs & RSAs, net





















14,482







145







(145)



























Issuance of common stock for acquisition of Visimid





















81,610







816







149,184























150,000



Stock-based compensation on stock options, RSUs & RSAs





































240,075























240,075



Foreign currency translation adjustment













































(125,208)















(125,208)



Net loss 





















































(1,342,376)







(1,342,376)



Balances at September 30, 2023





















37,455,438





$

374,554





$

243,217,458





$

481,328





$

(209,178,605)





$

34,894,735



Issuance of common stock for:

































































Exercise of Stock Options, RSUs & RSAs, net





















93,940







940







(940)



























Stock-based compensation on stock options, RSUs & RSAs





































258,691























258,691



Foreign currency translation adjustment













































259,973















259,973



Net loss 





















































(1,713,663)







(1,713,663)



Balances at December 31, 2023





















37,549,378





$

375,494





$

243,475,209





$

741,301





$

(210,892,268)





$

33,699,736



Issuance of common stock for:

































































Employee Stock Purchase Plan





















15,840







158







19,800























19,958



Exercise of Stock Options, RSUs & RSAs, net





















225,814







2,258







(2,258)



























Issuance of common stock for acquisition of Visimid





















267,176







2,672







333,382























336,054



Issuance of common stock under public equity placement





















68,041







680







97,528























98,208



Stock-based compensation on stock options, RSUs & RSAs





































264,492























264,492



Foreign currency translation adjustment













































(112,356)















(112,356)



Net loss  





















































(2,597,534)







(2,597,534)



Balances at March 31, 2024 





















38,126,249





$

381,262





$

244,188,153





$

628,945





$

(213,489,802)





$

31,708,558





































































Issuance of common stock for:

































































Exercise of Stock Options, RSUs & RSAs, net





















610,952







6,110







(6,110)



























Issuance of common stock under public equity placement





















517,442







5,174







702,950























708,124



Stock-based compensation on stock options, RSUs & RSAs





































255,765























255,765



Foreign currency translation adjustment













































(119,009)















(119,009)



Net loss





















































(2,353,773)







(2,353,773)



Balances at June 30, 2024





















39,254,643





$

392,546





$

245,140,758





$

509,936





$

(215,843,575)





$

30,199,665



 

LIGHTPATH TECHNOLOGIES, INC.

Condensed Consolidated Statements of Cash Flows

(unaudited)











Nine Months Ended

March 31,







2025





2024



Cash flows from operating activities:













Net loss



$

(7,795,091)





$

(5,653,573)



Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

















Depreciation and amortization





3,356,752







2,985,850



Interest from amortization of loan issuance costs





161,905











Loss on extinguishment of debt





418,502











Warrant issuance costs





318,777











Change in fair value of warrant liability





(904,694)











Loss on disposal of property and equipment





80,505







13,248



Stock-based compensation on stock options, RSUs & RSAs, net





745,155







763,258



Provision for credit losses





(3,014)







(4,422)



Change in operating lease assets and liabilities





(91,582)







47,693



Inventory write-offs to allowance





135,625







95,539



Deferred taxes





(2,368)







8,573



Changes in operating assets and liabilities, net of acquisitions:

















Trade accounts receivable





(822,043)







1,766,594



Other current assets





73,362







(419,797)



Inventories





(1,206,340)







725,460



Prepaid expenses and deposits





(360,439)







95,900



Accounts payable and accrued liabilities





520,289







32,020



Net cash (used in) provided by operating activities





(5,374,699)







456,343





















Cash flows from investing activities:

















Purchase of property and equipment





(580,726)







(1,892,660)



Proceeds from sale of equipment





10,648











Proceeds from sale-leaseback of equipment













364,710



Acquisition of G5





(20,250,011)











Acquisition of Visimid, net of cash acquired













(847,141)



Net cash used in investing activities





(20,820,089)







(2,375,091)





















Cash flows from financing activities:

















Proceeds from exercise of stock options





3,175











Proceeds from sale of common stock from Employee Stock Purchase Plan





14,385







39,677



Proceeds from issuance of common stock under public equity placement













98,208



Proceeds from issuance of common stock under private equity placement





437,725











Proceeds from issuance of preferred stock under private equity placement





18,842,138











Proceeds from issuance of warrants under private equity placement





4,313,813











Deferred payment for acquisition of Visimid





(125,000)











Borrowings on loans payable





6,659,596







142,853



Loan issuance costs





(597,465)











Payments on loans payable





(149,118)







(2,262,798)



Repayment of finance lease obligations





(133,711)







(87,610)



Net cash provided by (used in) financing activities





29,265,538







(2,069,670)





















Effect of exchange rate on cash and cash equivalents





(72,133)







2,880



Change in cash, cash equivalents and restricted cash





2,998,617







(3,985,538)



Cash, cash equivalents and restricted cash, beginning of period





3,480,268







7,144,490



Cash, cash equivalents and restricted cash, end of period



$

6,478,885





$

3,158,952





















Supplemental disclosure of cash flow information:

















Interest paid in cash



$

66,136





$

161,676



Income taxes paid



$

118,016





$

120,787



Supplemental disclosure of non-cash investing & financing activities:

















Purchase of equipment through finance lease arrangements



$

93,048





$

391,107



Issuance of common stock for acquisition of Visimid



$

713,946





$

486,054



 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lightpath-technologies-reports-third-quarter-fiscal-2025-financial-results-302456970.html

SOURCE LightPath Technologies

Latest News

May-16
May-16
May-15
May-15
May-14
May-08
May-07
May-07
May-07
Apr-30
Apr-09
Apr-03
Apr-01
Mar-31
Mar-18